TFEB and neoplasm: In 2019, Li and colleagues demonstrated that BRAFV600E-TFEB-ZKSCAN3-autophagy and lysosome biogenesis axis are involved in tumor resistance to targeted therapy in BRAF mutant melanomas, leading to the aberrant expression of TGF-beta pathway and impairing the tumor response to BRAF inhibition [76].